HAVCR1 and acute kidney injury: In this study, we verified that the main active ingredient of CS treatment significantly improved renal function as assessed by the reduction of SCr and BUN levels, morphological amelioration at 48 h after FA stimulation, and alleviation of NGAL and Kim-1 deposition, which are biomarkers for early-stage AKI diagnosis [46–49].